Philip Craig Andrews

Philip Craig Andrews

Auto-generated profile, based on publicly available information

Philip Craig Andrews

School of Chemistry, Monash University, Clayton, Melbourne, VIC 3800, Australia

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2021 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
DGDarren Griffith
Darren Griffith
HLHongyan Li
Hongyan Li
MWMelissa V. Werrett
Melissa V. Werrett
PAPhilip C. Andrews
Philip C. Andrews
HSHongzhe Sun
Hongzhe Sun
Bismuth-based compounds have been used extensively as medicines for the treatment of gastrointestinal disorders and H. pylori infections. Bismuth compounds and Bi-based nanomaterials show promise for emerging infectious diseases, cancer ( e.g. 213 Bi) and also imaging.

3 December 2018 in Chemical Reviews
Verified
Journal Article
Closed access
YOYih Ching Ong
Yih Ching Ong
SRSaonli Roy
Saonli Roy
PAPhilip C. Andrews
Philip C. Andrews
Gilles GasserGilles Gasser
Gilles Gasser

14 December 2018 in Advanced Energy Materials
Verified
Journal Article
Closed access
PDF file
NPNarendra Pai
Narendra Pai
JLJianfeng Lu
Jianfeng Lu
TGThomas R. Gengenbach
Thomas R. Gengenbach
ASAaron Seeber
Aaron Seeber
ACAnthony S. R. Chesman
Anthony S. R. Chesman
ASAlexandr N. Simonov
Alexandr N. Simonov

21 August 2006 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
PAPhilip C. Andrews
Philip C. Andrews
GDGlen Deacon
Glen Deacon
CFCraig M. Forsyth
Craig M. Forsyth
PJPeter Junk
Peter Junk
IKIsh Kumar
Ish Kumar
MMMelissa Maguire
Melissa Maguire

1 January 1996 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
GBGernot Boche
Gernot Boche
PAPhil Andrews
Phil Andrews
KHKlaus Harms
Klaus Harms
MMMichael Marsch
Michael Marsch
KRKanchugarakoppal S. Rangappa
Kanchugarakoppal S. Rangappa
CWChristoph Willeke
Christoph Willeke

27 September 2013 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
MAMuhammad Irshad Ali
Muhammad Irshad Ali
MRMuhammad Khawar Rauf
Muhammad Khawar Rauf
ABAmin Badshah
Amin Badshah
IKIsh Kumar
Ish Kumar
CFCraig M. Forsyth
Craig M. Forsyth
PAPhilip C. Andrews
Philip C. Andrews
In seeking new drugs for the treatment of the parasitic disease Leishmaniasis, an extensive range of organometallic antimony(V) dicarboxylates of the form [SbR3(O2CR′)2] have been synthesised, characterised and evaluated. The organometallic moieties (R) in the complexes vary in being Ph, tolyl (o, m or p), or benzyl. The carboxylates are predominantly substituted benzoates with some compounds incorporating acetato or cinnamato ligands. The crystal structures of [Sb(p-Tol)3(O2CC6H2-3,4,5-(OMe)3)2]·0.5PhMe and [SbPh3(m-CH3C6H4CH2CO2)2] were determined and shown to adopt a typical trigonal pyramidal geometry, being monomeric with a five coordinate Sb centre. In total, the biological activity of 26 Sb(V) compounds was assessed against the Leishmania major parasite, and also human fibroblast skin cells to give a measure of general toxicity. Of these, 11 compounds (predominantly substituted benzoates with m- or p-tolyl ligands) proved to be highly effective against the parasite amastigotes at concentrations of 0.5–3.5 μM, while being non-toxic towards the mammalian cells at levels below 25 μM, making them highly promising drug candidates.